¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Phosphofructokinase-1, Muscle Type"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
  • orbicularis oculi muscle
    ´«µÑ·¹±Ù, ¾È·û±Ù
  • orbicularis oris muscle
    ÀԵѷ¹±Ù, ±¸·û±Ù
  • occipitofrontal muscle
    µÚÅë¼öÀ̸¶±Ù, ÈĵÎÀüµÎ±Ù
  • piloerector muscle
    Åм¼¿ò±Ù, ÀÔ¸ð±Ù
  • piriform muscle
    ±ÃµÕ±¸¸Û±Ù, ÀÌ»ó±Ù
  • plantaris muscle
    ÀåµýÁöºø±Ù, Á·Ã´±Ù
  • platysma muscle flap
    ³ÐÀº¸ñ±ÙÆÇ
  • popliteus muscle
    ¿À±Ý±Ù, ½½¿Í±Ù
  • posterior cricoarytenoid muscle
    µÚ¹ÝÁö¸ð»Ô±Ù, ÈÄÀ±»óÇÇ¿­±Ù
  • papillary muscle
    ²ÀÁö±Ù, À¯µÎ±Ù
  • procerus muscle
    ´«»ì±Ù, ºñ±Ù±Ù
  • pronator quadratus muscle
    ³×¸ð¾þħ±Ù, ¹æÇüȸ³»±Ù
  • pronator teres muscle
    ¿ø¾þħ±Ù, ¿øÇüȸ³»±Ù
  • psoas muscle
    Ç㸮±Ù, ¿ä±Ù
  • pterygoid muscle
    ³¯°³±Ù, ÀÍ»ó±Ù
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
  • lumbrical muscle
    ¹ú·¹±Ù
  • muscle
    ±ÙÀ°
  • masseter muscle
    ±ú¹°±Ù
  • massetric muscle transfer
    ±ú¹°±ÙÀüÀ̼ú
  • masticatory muscle
    ¾Ã±â±ÙÀ°, ÀúÀÛ±Ù
  • microneurovascular muscle transfer
    ¹Ì¼¼½Å°æÇ÷°ü±ÙÀ°ÀüÀ̼ú
  • multifidus muscle
    ¹µ°¥·¡±Ù
  • multipennate muscle
    ¹µ±ê±ÙÀ°
  • muscle relaxant
    ±ÙÀ°Ç®¸²Á¦, ±ÙÀ°ÀÌ¿ÏÁ¦
  • muscle sense
    ±ÙÀ°°¨°¢
  • muscle sound
    ±ÙÀ°À½
  • muscle spasm
    ±ÙÀ°¿¬Ãà
  • muscle spindle
    ±ÙÀ°¹æÃß
  • muscle stimulant
    ±ÙÀ°ÀÚ±ØÁ¦
  • muscle strength
    ±ÙÀ°Èû, ±Ù·Â
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
  • inferior tarsal muscle
    ÇÏ°ËÆÇ±Ù.
  • inferior tarsal muscle
    ¾Æ·¡´«²¨Ç®ÆÇ±Ù
  • inspiratory muscle
    Èí½Ä±Ù.
  • peroneal muscle ³ª musculus f.
    ºñ°ñ±Ù(ÝëÍéÐÉ).
  • peroneus longus muscle ³ª musculus fibularis lon gus
    ±äºñ°ñ±Ù, Àåºñ°ñ±Ù(íþÝëÍéÐÉ).
  • peroneus longus muscle ³ª musculus fibularis lon gus
    ±äºñ°ñ±Ù, Àåºñ°ñ±Ù(íþÝëÍéÐÉ).
  • pharyngeal constrictor muscle
    ÀεμöÃà±Ù
  • pharyngeal muscle
    ÀεαÙ(ìÖÔéÐÉ).
  • pharyngeal muscle
    ÀεαÙ(ìÖÔéÐÉ).
  • pharyngoglossal muscle
    Àεμ³±Ù(ìÖÔé àßÐÉ).
  • pharyngoglossal muscle
    Àεμ³±Ù
  • piloerector muscle
    ÀÔ¸ð±Ù(í¡Ù¾ÐÉ).
  • piloerector muscle
    ÀÔ¸ð±Ù(í¡Ù¾ÐÉ)
  • piriform muscle ³ª musculus piriformis
    Á¶·Õ¹Ú±Ù, ÀÌ»ó±Ù(ì±ßÒÐÉ).
  • plain muscle =smooth m. unstriated musculus, un striped musculus
    ÆòȰ±Ù(øÁüÁÐÉ) ºÒ¼öÀDZÙ(ÝÕâËëòÐÉ) .
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
  • hypersensitivity reactions,type iii(imune complex-mediated)
    IIIÇü
  • hypersensitivity reactions,type iv(cell-mediated)
    IVÇü
  • hypersensitivity, delayed-type
    Áö¿¬Çü °ú¹Î¹ÝÀÀ
  • hypersensitivity, immediate-type
    Áï½ÃÇü °ú¹Î¹ÝÀÀ
  • hypertrophic type
    ºñ´ëÇü
  • hypogammaglobulinemia, Swiss-type
    ½ºÀ§½ºÇü °¨¸¶±Û·ÎºÒ¸°ÀúÇ÷Áõ
  • intermediate type
    Áß°£Çü(ñéÊàúþ) ¡ìÇãÇ÷¼º Áúȯ(úÈúìàõòðü´)ÀÇ¡í.
  • intracanalicular type
    ¼Ò°ü³»Çü
  • introversion type
    ³»ÇâÇü(Ò®ú¾úþ)
  • intuitive type
    Á÷°üÇü(òÁκúþ)
  • irregular type
    ºÒ±ÔÄ¢Çü
  • jealous type
    ÁúÅõÇü(òì÷àúþ)
  • langhans-type giant cell
    ¶û±×Çѽº°Å´ë¼¼Æ÷, Langerhans °Å´ë¼¼Æ÷(¡­ËÝÓÞá¬øà)
  • lepromatous type
    ³ªÁ¾Çü(ÑÛðþúþ)
  • lepromatous type
    ³ªÁ¾Çü(ÑÛðþúþ).
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 12
DTH delayed-type hypersensitivity; Diploma in Tropical Hygiene
EBDCT Cockayne-Touraine type of epidermolysis bullosa dystrophica
ECL emitter-coupled logic; enterochromaffin-like [type]; euglobin clot lysis
HIB heart infusion broth; hemolytic immune body; Hemophilus influenzae type B [vaccine]
HITB, HiTB Hemophilus influenzae type B
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 12
RMS Respiratory muscle strength
SMC SMOOTH MUSCLE CELL
SM Skeletal muscle
SMV Skeletal muscle ventricle
SM Smooth muscle
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • muscle activity
    ±Ù Ȱ¼º
  • muscle atrophy
    ±Ù À§Ãà
  • muscle biopsy
    ±Ù »ý°Ë
    °ñ°Ý±ÙÀÇ ÀϺθ¦ ÀýÁ¦ÇÏ¿© Á¶Á÷ÇÐÀûÀ¸·Î °Ë»öÇÏ´Â ¹æ¹ýÀ¸·Î¼­, ½Å°æ±Ù ÁúȯÀÇ Áø´Ü, º´Å ÆÄ¾ÇÀÇ ÇÑ ÀÚ·á·Î »ï´Â´Ù. ¶Ç Çʿ信 µû¶ó¼­ ±Ù Á¶Á÷³» ¹°ÁúÀÇ »ýÈ­ÇÐÀû ºÐ¼®À» ½Ç½ÃÇÑ´Ù. äÃëÇÑ ±ÙÀ°Àº ¼öÃàÇϹǷΠ½ÅÀü±â·Î ´Ã·Á¼­ Æ÷¸£¸»¸° °íÁ¤À» ÇÑ´Ù. Àý°³´Â ±Ù ¼¶À¯ÀÇ ±æÀÌ ¹æÇâÀ¸·Î ÀÚ¸£´Â Á¾´Ü¸é°ú Áö°¢À¸·Î ÀÚ¸£´Â Ⱦ´Ü¸é°úÀÇ 2¹æÇâÀ¸·Î Àß¶ó³» Ç¥º»À» ¸¸µé¾î¼­ °Ë»öÇÑ´Ù. ±Ù »ý°Ë¿¡ ÀÇÇØ ±ÙÀÌ¿µ¾çÁõ, ÇǺΠ±Ù¿° µî ±ÙÀÇ º¯¼ºÀ̳ª ¿°ÁõÀÇ »óŸ¦ ¾Ë ¼ö°¡ ÀÖ´Ù.
  • muscle cell
    ±Ù ¼¼Æ÷
    ´Éµ¿ÀûÀ¸·Î ¼öÃ༺À» º¸ÀÌ´Â µ¿¹°Ã¼³»ÀÇ ¼¼Æ÷. ±ÙÀ° ¼¼Æ÷¶ó°íµµ ÇÑ´Ù. ±Ù Á¶Á÷À» ±¸¼ºÇÏ´Â °æ¿ì °¢°¢ÀÇ ±Ù ¼¼Æ÷´Â ÀϹÝÀûÀ¸·Î ¹æÃß»ó ¶Ç´Â ¼¶À¯»óÀ» ¶í´Ù. ÇØ¸éµ¿¹°Àº ±ÙÁ¶Á÷ÀÌ ¾øÀ¸³ª, ±Ô°¢ ÇØ¸é·ù¿¡¼­´Â üǥÀÇ ÆíÆò»óÇÇ ¼¼Æ÷°¡ ¾ó¸¶°£ ¼öÃ༺À» °¡Áö¸ç, üǥ ƯÈ÷ À¯Ãâ°ø ÁÖº¯¿¡ ¹Ì¿À»çÀÌÆ®¶ó°í ÇÏ´Â ±ä ¹æÃßÇüÀÇ ¼öÃ༺ ¼¼Æ÷°¡ Á¸ÀçÇÑ´Ù. ¶Ç ¼®È¸ ÇØ¸é·ùÀÇ ¼Ò°ø ¼¼Æ÷¿¡µµ ¼öÃ༺ÀÌ ÀÎÁ¤µÈ´Ù. À̵éÀº ¾î¶² Á¾·ùÀÇ ¿ø»ýµ¿¹° ¸ö Àüü¿¡ ³ªÅ¸³ª´Â ¼öÃ༺°ú ´õºÒ¾î ±Ù ¼¼Æ÷°¡ ³ªÅ¸³ª´Â ½ÃÀÛ ÇüÅ·Π°£ÁֵȴÙ. °­À嵿¹°ÀÇ Æú¸³Çü¿¡¼­´Â ¿Ü¹è¿± ¼¼Æ÷ Ãþ ¼Ó¿¡ ÀÖ´Â »óÇÇ ±Ù ¼¼Æ÷¿¡ ÁøÁ¤ÇÑ ±Ù¿ø¼¶À¯°¡ ÀÖ´Ù. À̰ÍÀº °¡Àå ÈçÈ÷ ÀÖ´Â ¿øÁÖ»óÇÇ ¼¼Æ÷, ÁïÁöÁö ¼¼Æ÷ÀÇ ±âÀúºÎ°¡ ¹æÃßÇüÀ¸·Î ´Ã¾î³ª¼­ ±× ºÎºÐ¿¡ ÇÑÇØ¼­ ±Ù¿ø¼¶À¯°¡ Á¸ÀçÇÏ´Â °ÍÀ¸·Î, üǥÀÇ »óÇÇ ¼¼Æ÷¿¡¼­ ±Ù¼¼Æ÷·Î ºÐÈ­ÇÏ´Â µµÁßÀÇ °ÍÀÌ´Ù. ÇØÆÄ¸® Çü¿¡¼­´Â ¹æÃßÇü ±Ù ¼¼Æ÷°¡ ¿Ï¼ºµÈ´Ù. ÆíÇüµ¿¹° À̻󿡼­´Â ÇDZÙÃþ, ±â°ü±Ù µî ºÐÈ­°¡ ÇöÀúÇÏ´Ù.
  • muscle compartment syndrome
    ±Ù ±¸¿ª ÁõÈıº
    ±Ù ±¸¿ª ³»ÀÇ »ê¼Ò ºÎÁ·À¸·Î ÀÎÇÏ¿© ±ÙÀ°¿¡ ÅëÁõÀ̳ª »»»»ÇÔÀÌ ¹ß»ýÇÑ °Í.
  • muscle conditioning exercise
    ±Ù Á¶°ÇÈ­ ¿îµ¿
  • muscle contraction headache
    ±Ù ±äÀ强 µÎÅë, ±Ù ¼öÃ༺ µÎÅë
    °¡Àå ºóµµ°¡ ¸¹Àº µÎºÎ³ª °æºÎ ±ÙÀ°ÀÇ ¸¸¼ºÀû ¼öÃà¿¡ ±âÀÎÇÑ´Ù. µÐÇϰí ÁËÀÌ´Â °Í °°Àº Áö¼ÓÀûÀÎ ¾Ð¹Ú¼ºÀÇ ÅëÁõÀÌ°í ¼öÀÏ ³»Áö ¼ö°³¿ù °è¼ÓµÈ´Ù. ÀÏ»ó »ýȰÀÇ ½ºÆ®·¹½º¿¡ ´ëÇÑ °³Ã¼ ¹ÝÀÀÀ¸·Î¼­ »ý±â°í ¿ÀÈĺÎÅÍ Àú³á¿¡ ´õ¿í ½ÉÇØÁø´Ù. ±äÀ强 µÎÅëÀ¸·Î ÀÏÄþîÁö´Â °ÍÀº ´ëºÎºÐÀÌ À̰Ϳ¡ Æ÷ÇԵȴÙ. °¡º­¿î ¿ì¿ï °æÇâÀ» º¸ÀÌ´Â °æ¿ì°¡ ¸¹´Ù. ¸À»çÁö, ¿­ ÁÖ¸Ó´Ï, ±Ù ÀÌ¿ÏÁ¦, Ç׿ì¿ïÁ¦, ¹ÙÀÌ¿ÀÇǵå¹é ±Ù À̿Ϲý µîÀÌ È¿°ú°¡ ÀÖ´Ù.
  • muscle corpuscle
    ±Ù ¼Òü
  • muscle disorder
    ±ÙÀ° Àå¾Ö, ±Ù Àå¾Ö
  • muscle disuse atrophy
    Æó¿ë¼º ±Ù À§Ãà
  • muscle effect
    ±ÙÀ° È¿°ú
  • muscle fatigue
    ±ÙÀ° ÇÇ·Î, ±Ù ÇÇ·Î
    ½Å°æ±Ù Ç¥º»ÀÇ ½Å°æÀ» µÇÇ®ÀÌÇØ¼­ Àü±â ÀÚ±ØÇÏ°í ±ÙÀ» ½¯»õ¾øÀÌ ¼öÃà½ÃŰ¸é °á±¹¿¡´Â ±ÙÀÌ ¼öÃàÇÏÁö ¾Ê°Ô µÈ´Ù. À̶§ ±Ù ±× ÀÚü¿¡ Àü·ù¸¦ ÁýÁß½ÃŰ°í ±ÙÀ» Á÷Á¢ ÀÚ±ØÇÏ¸é ±ÙÀº ´Ù½Ã ¼öÃàÇϴµ¥ ÀÌ ¹æ¹ýÀ¸·Îµµ ¼öÃàÀ» °è¼ÓÇÒ ¼ö°¡ ¾ø°Ô µÈ´Ù. ÀÌ¿Í °°Àº »óŸ¦ ±Ù ÇǷζó°í ÇÑ´Ù.
  • muscle fibril
    ±Ù¿ø ¼¶À¯
    µ¿ÀǾî=myofibril.
  • muscle force
    ±Ù·Â
    µ¿ÀǾî=muscle strength.
  • muscle graft
    ±ÙÀ° À̽Ä
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 12
type II hyperlipoproteinaemia <biochemistry> A relatively rare (7 out of 1,000) genetic disease in which there is elevation in the blood triglycerides, cholesterol and low density lipoprotein (LDL). Also called type II hyperlipoproteinaemia, familial hyperlipoproteinaemia or familial hypercholesterolaemia.
Origin: Gr. Haima = blood
(27 Sep 1997)
type III acrocephalosyndactyly An autosomal dominant syndrome with variable expression of brachycephaly, maxillary hypoplasia, prominent ear crus, syndactyly, facial asymmetry, shallow orbits, telecanthus, and nasal septal deviation; may show mental retardation.
Synonym: Saethre-Chotzen syndrome.
(05 Mar 2000)
type III collagen Collagen characteristic of reticular fibres.
(05 Mar 2000)
type III familial hyperlipoproteinaemia Hyperlipoproteinaemia characterised by increased plasma levels of LDL, beta-lipoproteins, pre-beta-lipoproteins, cholesterol, phospholipids, and triglycerides; hypertriglyceridemia induced by a high carbohydrate diet, and glucose tolerance is abnormal; frequent eruptive xanthomas and atheromatosis, particularly coronary artery disease; biochemical defect lies in apolipoproteins; there are many varieties.
Synonym: carbohydrate-induced hyperlipaemia, dysbetalipoproteinaemia, familial hyperbetalipoproteinaemia and hyperprebetalipoproteinaemia, familial hypercholesterolaemia with hyperlipaemia.
(05 Mar 2000)
type III hyperlipoproteinaemia <biochemistry> An inherited disorder (gene defect) where both cholesterol and triglycerides are elevated in the same patient. This condition accelerates the effects of atherosclerosis and thus increases the risk of cardiovascular disease. Conditions such as hypothyroidism, obesity and diabetes enhances this risk.
Origin: Gr. Haima = blood
(27 Sep 1997)
type III hypersensitivity reaction An immunologic category of diseases evoked by the deposition of antigen-antibody or antigen-antibody-complement complexes on cell surfaces, with subsequent involvement of breakdown products of complement, platelets, and polymorphonuclear leukocytes, and development of vasculitis; nephritis is common. Arthus phenomenon and serum sickness are classic examples, but many other disorders, including most of the connective tissue disease's, may belong in this immunologic category; immune complex disease's can also occur during a variety of disease's of known aetiology, such as subacute bacterial endocarditis.
See: autoimmune disease.
Synonym: immune complex disorder, type III hypersensitivity reaction.
(05 Mar 2000)
type III mucopolysaccharidosis <syndrome> An error of the mucopolysaccharide metabolism, with excretion of large amounts of heparan sulfate in the urine and severe mental retardation with hepatomegaly; skeleton may be normal or may present mild changes similar to those in Hurler's syndrome; several different types (A, B, C, and D) have been identified according to the enzyme deficiency; autosomal recessive inheritance.
Synonym: type III mucopolysaccharidosis.
(05 Mar 2000)
type II interferon <chemical> The major interferon produced by mitogenically or antigenically stimulated lymphocytes. It is structurally different from type I interferon (interferon type I) and its major activity is immunoregulation. It has been implicated in the expression of class II histocompatibility antigens in cells that do not normally produce them, leading to autoimmune disease.
Pharmacological action: antineoplastic agent, antiviral agents.
Chemical name: Interferon-gamma (human lymphocyte protein moiety reduced)
(12 Dec 1998)
type II mortality <epidemiology> A mortality schedule in which all hosts are assumed to die at a constant rate. This constant rate is equal to the inverse of the life expectancy.
(05 Dec 1998)
type II mucopolysaccharidosis <syndrome> An error of mucopolysaccharide metabolism characterised by deficiency of iduronate sulfatase, with excretion of dermatan sulfate and heparan sulfate in the urine; clinically similar to Hurler's syndrome but distinguished by less severe skeletal changes, no corneal clouding, and X-linked recessive inheritance.
Synonym: type II mucopolysaccharidosis.
(05 Mar 2000)
type I interferon <chemical> Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (interferon-alpha and interferon-beta).
Pharmacological action: antineoplastic agent, antiviral agents.
(12 Dec 1998)
type I mortality <epidemiology> A mortality schedule in which all hosts are assumed to live for a fixed number of years equal to the life expectancy.
(05 Dec 1998)
type IS mucopolysaccharidosis <syndrome> A hereditary metabolic disorder caused by a recessive gene which results in a deficiency of the enzyme alpha-L-iduronidase, which breaks down dermatan sulphate and heparan sulphate, two types of mucopolysaccharides (complex carbohydrates). Consequently, the mucopolysaccharides accumulate in the cells of the body and cause damage.
Symptoms include skeletal deformities, mental retardation, coronary artery disease, deafness, and stiff joints, among other things. There are mild and severe forms of the syndrome, the severe form is called Hurler syndrome, the mild form is called Scheie Syndrome, and children with an intermediate form have Hurler-Scheie Syndrome. Patients with the mild form generally suffer little to no mental retardation and survive to adulthood. There is presently no cure. Scheie's Syndrome is one of a number of related rare genetic mucopolysaccharide disorders, the most common being Hunter syndrome.
(09 Oct 1997)
type IVA,B mucopolysaccharidosis <syndrome> An error of mucopolysaccharide metabolism with excretion of keratan sulfate in urine; characterised by severe skeletal defects with short stature, severe deformity of spine and thorax, long bones with irregular epiphyses but with shafts of normal length, enlarged joints, flaccid ligaments, and waddling gait; autosomal recessive inheritance; type IV A mucopolysaccharidosis is due to an absence of galactose-1-sulfatase, while type IV B is due to a deficiency of a beta-galactosidase.
Synonym: Brailsford-Morquio disease, Morquio's disease, Morquio-Ullrich disease, type IVA, B mucopolysaccharidosis.
(05 Mar 2000)
type IV acrocephalosyndactyly Acrocephalosyndactyly with pointed nose, hypertelorism, cleft palate, congenital heart disease and pseudohermaphroditism; contractures of elbows and knees; soft tissue syndactyly, absent first metatarsal and great toe. Autosomal recessive.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 12
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 12
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 12
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 12
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 12
ÅëÇÕ°Ë»ö ¿Ï·á